Giulia Acconci
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Giulia Acconci has a total of 8 co-authors. Here are the top co-authors by number of shared publications:
- Chiara Finale
Department of Oncology, Azienda USL Toscana Nord Ovest, 56121 Pisa, Italy
1 shared publication - Giacomo Allegrini
Department of Oncology, Azienda USL Toscana Nord Ovest, 56121 Pisa, Italy
1 shared publication - Gianna Musettini
Department of Oncology, Azienda USL Toscana Nord Ovest, 56121 Pisa, Italy
1 shared publication - Guido Bocci
Department of Translational Research and New Technologies in Medicine and Surgery, University of Pisa, 56126 Pisa, Italy
1 shared publication - Linda Bartalini
Department of Oncology, Azienda USL Toscana Nord Ovest, 56121 Pisa, Italy
1 shared publication - Luigi Coltelli
Department of Oncology, Azienda USL Toscana Nord Ovest, 56121 Pisa, Italy
1 shared publication
Latest Publications
- Open Access
- 9 August 2026
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 15 (16) , 6172
A Perspective on a Possible New Role for Bevacizumab Combined with Paclitaxel in Hormone-Resistant Metastatic Breast-Cancer Patients
Cyclin-Dependent Kinase 4/6 inhibitors (CDK 4/6i) represented a paradigm shift in the treatment of patients with metastatic hormone-receptor-positive (HR+), HER2-negative (HER2-) breast cancer patients. When disease progression occurs and further hormonal manipulations or target therapies fail, chemotherapy remains a therapeutic choice. For these reasons, resources should be invested in redesigning the best treatment strategy with the current chemotherapy drugs available. Nevertheless, the preferred strategy typically remains a planned sequence of single chemotherapeutic agents. This approach endeavors to extend overall survival and maintain quality of life. Within this complex and evolving therapeutic scenario, where the necessity for effective and treatment options is crucial, we explore in the present paper a perspective for a hypothetical new role of bevacizumab combined with paclitaxel for patients with metastatic HR+, HER2- breast cancer patients resistant to hormone therapy. Recent findings from our preliminary published pharmacogenetic studies, could suggest the efficacy of bevacizumab as linked to a well-defined genomic profile of genes implicated in the process of neoangiogenesis (e.g., favorable profile: VEGF-A rs833061/VEGFR-2 rs1870377: CT/AT, CT/AA, TT/AA, TT/TT, CC/TT), concluding the present perspective underlying the fact that bevacizumab combined with paclitaxel will be reconsidered with this new potential use only if well-designed prospective trials confirm what has been observed from our retrospective data.
- 9 August 2026
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 15 (16) , 6172
Open AccessA Perspective on a Possible New Role for Bevacizumab Combined with Paclitaxel in Hormone-Resistant Metastatic Breast-Cancer Patients
Cyclin-Dependent Kinase 4/6 inhibitors (CDK 4/6i) represented a paradigm shift in the treatment of patients with metastatic hormone-receptor-positive (HR+), HER2-negative (HER2-) breast cancer patients. When disease progression occurs and further hormonal manipulations or target therapies fail, chemotherapy remains a therapeutic choice. For these reasons, resources should be invested in redesigning the best treatment strategy with the current chemotherapy drugs available. Nevertheless, the preferred strategy typically remains a planned sequence of single chemotherapeutic agents. This approach endeavors to extend overall survival and maintain quality of life. Within this complex and evolving therapeutic scenario, where the necessity for effective and treatment options is crucial, we explore in the present paper a perspective for a hypothetical new role of bevacizumab combined with paclitaxel for patients with metastatic HR+, HER2- breast cancer patients resistant to hormone therapy. Recent findings from our preliminary published pharmacogenetic studies, could suggest the efficacy of bevacizumab as linked to a well-defined genomic profile of genes implicated in the process of neoangiogenesis (e.g., favorable profile: VEGF-A rs833061/VEGFR-2 rs1870377: CT/AT, CT/AA, TT/AA, TT/TT, CC/TT), concluding the present perspective underlying the fact that bevacizumab combined with paclitaxel will be reconsidered with this new potential use only if well-designed prospective trials confirm what has been observed from our retrospective data.